How we Investigate Bone Marrow Failure Syndromes in Pediatric Patients.

IF 1.4 4区 医学 Q4 HEMATOLOGY
Pediatric Hematology and Oncology Pub Date : 2026-08-01 Epub Date: 2026-06-01 DOI:10.1080/08880018.2026.2676558
Marilia Bazzo Catto, David J Young, Luiz Fernando Bazzo Catto
{"title":"How we Investigate Bone Marrow Failure Syndromes in Pediatric Patients.","authors":"Marilia Bazzo Catto, David J Young, Luiz Fernando Bazzo Catto","doi":"10.1080/08880018.2026.2676558","DOIUrl":null,"url":null,"abstract":"<p><p>Bone marrow failure syndromes (BMFS) encompass a spectrum of acquired and constitutional disorders characterized by impaired hematopoiesis and cytopenias. In pediatric patients, constitutional BMFS represent up to 50% of cases, yet their diagnosis remains challenging due to subtle or absent extra-hematologic manifestations that mimic immune aplastic anemia. Accurate differentiation is essential, as it directly influences prognosis, therapeutic strategy, surveillance for extra-hematopoietic complications, and donor selection for hematopoietic cell transplantation. This review presents a structured diagnostic framework for pediatric BMFS, integrating clinical history, physical examination, bone marrow morphology, flow cytometry, cytogenetic analysis, disease-specific functional assays, and next-generation sequencing (NGS). Chromosomal breakage testing remains the gold-standard assay for Fanconi anemia, while telomere length measurement is the strongest predictor for differentiating constitutional from immune BMF. NGS enables comprehensive germline variant detection, resolves diagnostically ambiguous presentations, and informs genotype-guided familial screening. Recognition of disease-specific patterns of clonal hematopoiesis further refines diagnostic precision and risk stratification. A stepwise, evidence-based approach is essential to optimize early diagnosis and long-term outcomes in pediatric patients with BMFS.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"268-290"},"PeriodicalIF":1.4000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08880018.2026.2676558","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/1 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Bone marrow failure syndromes (BMFS) encompass a spectrum of acquired and constitutional disorders characterized by impaired hematopoiesis and cytopenias. In pediatric patients, constitutional BMFS represent up to 50% of cases, yet their diagnosis remains challenging due to subtle or absent extra-hematologic manifestations that mimic immune aplastic anemia. Accurate differentiation is essential, as it directly influences prognosis, therapeutic strategy, surveillance for extra-hematopoietic complications, and donor selection for hematopoietic cell transplantation. This review presents a structured diagnostic framework for pediatric BMFS, integrating clinical history, physical examination, bone marrow morphology, flow cytometry, cytogenetic analysis, disease-specific functional assays, and next-generation sequencing (NGS). Chromosomal breakage testing remains the gold-standard assay for Fanconi anemia, while telomere length measurement is the strongest predictor for differentiating constitutional from immune BMF. NGS enables comprehensive germline variant detection, resolves diagnostically ambiguous presentations, and informs genotype-guided familial screening. Recognition of disease-specific patterns of clonal hematopoiesis further refines diagnostic precision and risk stratification. A stepwise, evidence-based approach is essential to optimize early diagnosis and long-term outcomes in pediatric patients with BMFS.

我们如何研究小儿患者骨髓衰竭综合征。
骨髓衰竭综合征(BMFS)包括一系列以造血功能受损和细胞减少为特征的获得性和体质疾病。在儿科患者中,体质性BMFS占病例的50%,但由于类似免疫再生障碍性贫血的微妙或缺乏血液学外表现,其诊断仍然具有挑战性。准确的分化是至关重要的,因为它直接影响预后、治疗策略、对造血外并发症的监测以及造血细胞移植的供体选择。这篇综述提出了一个结构化的儿科BMFS诊断框架,包括临床病史、体格检查、骨髓形态学、流式细胞术、细胞遗传学分析、疾病特异性功能测定和下一代测序(NGS)。染色体断裂检测仍然是范可尼贫血的金标准检测,而端粒长度测量是区分体质性和免疫性BMF的最强预测指标。NGS能够实现全面的种系变异检测,解决诊断上的模糊表现,并为基因型指导的家族筛查提供信息。对克隆造血疾病特异性模式的识别进一步提高了诊断精度和风险分层。循序渐进的循证方法对于优化小儿BMFS患者的早期诊断和长期预后至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.60
自引率
5.90%
发文量
71
审稿时长
6-12 weeks
期刊介绍: PHO: Pediatric Hematology and Oncology covers all aspects of research and patient management within the area of blood disorders and malignant diseases of childhood. Our goal is to make PHO: Pediatric Hematology and Oncology the premier journal for the international community of clinicians and scientists who together aim to define optimal therapeutic strategies for children and young adults with cancer and blood disorders. The journal supports articles that address research in diverse clinical settings, exceptional case studies/series that add novel insights into pathogenesis and/or clinical care, and reviews highlighting discoveries and challenges emerging from consortia and conferences. Clinical studies as well as basic and translational research reports regarding cancer pathogenesis, genetics, molecular diagnostics, pharmacology, stem cells, molecular targeting, cellular and immune therapies and transplantation are of interest. Papers with a focus on supportive care, late effects and on related ethical, legal, psychological, social, cultural, or historical aspects of these fields are also appreciated. Reviews on important developments in the field are welcome. Articles from scientists and clinicians across the international community of Pediatric Hematology and Oncology are considered for publication. The journal is not dependent on or connected with any organization or society. All submissions undergo rigorous peer review prior to publication. Our Editorial Board includes experts in Pediatric Hematology and Oncology representing a wide range of academic and geographic diversity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书